Tumor antigen‑specific interleukin‑10‑producing T‑cell response in patients with head and neck squamous cell carcinoma

Horikawa,Momoka; Masuda,Kei; Takahashi,Hideyuki; Tada,Hiroe; Tomidokoro,Yuichi; Motegi,Masaomi; Oyama,Tetsunari; Takeda,Shigeki; Chikamatsu,Kazuaki

doi:10.3892/ol.2024.14589

Tumor antigen‑specific interleukin‑10‑producing T‑cell response in patients with head and neck squamous cell carcinoma

Authors:
- Momoka Horikawa
- Kei Masuda
- Hideyuki Takahashi
- Hiroe Tada
- Yuichi Tomidokoro
- Masaomi Motegi
- Tetsunari Oyama
- Shigeki Takeda
- Kazuaki Chikamatsu
View Affiliations

Affiliations: Faculty of Science and Technology, Division of Molecular Science, Gunma University, Kiryu, Gunma 376‑8515, Japan, Department of Pathology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371‑8511, Japan, Department of Otolaryngology‑Head and Neck Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma 371‑8511, Japan
Published online on: July 24, 2024 https://doi.org/10.3892/ol.2024.14589
Article Number: 456
Copyright: © Horikawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interleukin‑10 (IL‑10) is a highly pleiotropic cytokine that regulates immunological homeostasis through anti‑inflammatory and/or immunostimulatory functions. Moreover, IL‑10 is well known to exert diverse roles in tumor immunology and immunotherapy. The present study investigated the presence of circulating tumor antigen‑specific IL‑10‑producing T cells in patients with head and neck squamous cell carcinoma (HNSCC), and determined factors that may influence the immunodynamics of IL‑10‑producing T cells. In vitro, peripheral blood mononuclear cells (PBMCs) stimulated with the tumor antigens p53 and MAGE‑A4 were evaluated for interferon (IFN)‑γ/IL‑10 production using the IFN‑γ/IL‑10 double‑color enzyme‑linked immunosorbent spot assay. The proportion of T cells expressing immune checkpoint molecules in PBMCs was analyzed using flow cytometry. Of the 18 patients with HNSCC, 2 (11.1%) and 9 (50.0%) exhibited p53‑specific IFN‑γ and IL‑10 production, respectively. Meanwhile, MAGE‑A4‑specific IFN‑γ and IL‑10 production was detected in 4 (28.6%) and 7 (50.0%) of 14 patients. In the p53‑specific responses, IL‑10‑producing T cells were observed in significantly more patients than IFN‑γ producing T cells (P=0.0275). In both CD4⁺ and CD8⁺ T cells, the proportion of T cells expressing lymphocyte activation gene‑3 (Lag‑3) was significantly lower in patients with p53‑specific IL‑10 production than in those without. In certain patients, Lag‑3 blockade enhanced tumor antigen‑specific IL‑10. Taken together, the present study successfully demonstrated that tumor antigen‑specific IL‑10‑producing T cells exist in the peripheral blood of patients with HNSCC and that Lag‑3⁺ T cells may serve an important role in modulating IL‑10‑producing T cells. These findings provide novel insights into the roles of IL‑10 and Lag‑3 in mediating antitumor immune responses.

View Figures

View References

1	Carlini V, Noonan DM, Abdalalem E, Goletti D, Sansone C, Calabrone L and Albini A: The multifaceted nature of IL-10: Regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front Immunol. 14:11610672023. View Article : Google Scholar
2	Mocellin S, Panelli MC, Wang E, Nagorsen D and Marincola FM: The dual role of IL-10. Trends Immunol. 24:36–43. 2003. View Article : Google Scholar
3	Saraiva M, Vieira P and O'Garra A: Biology and therapeutic potential of interleukin-10. J Exp Med. 217:e201904182020. View Article : Google Scholar
4	Fujimura T, Kambayashi Y and Aiba S: Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth. Oncoimmunology. 1:1433–1434. 2012. View Article : Google Scholar
5	Pan Y, Yu Y, Wang X and Zhang T: Tumor-associated macrophages in tumor immunity. Front Immunol. 11:5830842020. View Article : Google Scholar
6	Emmerich J, Mumm JB, Chan IH, LaFace D, Truong H, McClanahan T, Gorman DM and Oft M: IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res. 72:3570–3581. 2012. View Article : Google Scholar
7	Guo Y, Xie YQ, Gao M, Zhao Y, Franco F, Wenes M, Siddiqui I, Bevilacqua A, Wang H, Yang H, et al: Metabolic reprogramming of terminally exhausted CD8⁺ T cells by IL-10 enhances anti-tumor immunity. Nat Immunol. 22:746–756. 2021. View Article : Google Scholar
8	Oft M: IL-10: Master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res. 2:194–199. 2014. View Article : Google Scholar
9	Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR and Fang Y: The paradoxical role of IL-10 in immunity and cancer. Cancer Lett. 367:103–107. 2015. View Article : Google Scholar
10	Jankovic D, Kugler DG and Sher A: IL-10 production by CD4+ effector T cells: A mechanism for self-regulation. Mucosal Immunol. 3:239–246. 2010. View Article : Google Scholar
11	Roncarolo MG, Gregori S, Bacchetta R, Battaglia M and Gagliani N: The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases. Immunity. 49:1004–1019. 2018. View Article : Google Scholar
12	Vence L, Palucka AK, Fay JW, Ito T, Liu YJ, Banchereau J and Ueno H: Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci USA. 104:20884–20889. 2007. View Article : Google Scholar
13	Wang HY, Peng G, Guo Z, Shevach EM and Wang RF: Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol. 174:2661–2670. 2005. View Article : Google Scholar
14	Bonertz A, Weitz J, Pietsch DHK, Rahbari NN, Schlude C, Ge Y, Juenger S, Vlodavsky I, Khazaie K, Jaeger D, et al: Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest. 119:3311–3321. 2009.
15	Yamada K, Masuda K, Ida S, Tada H, Bando M, Abe K, Tatematsu KI, Sezutsu H, Oyama T, Chikamatsu K and Takeda S: In vitro assessment of antitumor immune responses using tumor antigen proteins produced by transgenic silkworms. J Mater Sci Mater Med. 32:582021. View Article : Google Scholar
16	Tada H, Takahashi H, Yamada K, Masuda K, Nagata Y, Uchida M, Shino M, Ida S, Mito I, Matsuyama T, et al: Dynamic alterations of circulating T lymphocytes and the clinical response in patients with head and neck squamous cell carcinoma treated with nivolumab. Cancer Immunol Immunother. 71:851–863. 2022. View Article : Google Scholar
17	Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E and Scheibenbogen C: Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res. 60:4850–4854. 2000.
18	Duray A, Demoulin S, Hubert P, Delvenne P and Saussez S: Immune suppression in head and neck cancers: A review. Clin Dev Immunol. 2010:7016572010.
19	Kostecki KL, Iida M, Crossman BE, Salgia R, Harari PM, Bruce JY and Wheeler DL: Immune escape strategies in head and neck cancer: Evade, resist, inhibit, recruit. Cancers (Basel). 16:3122024. View Article : Google Scholar
20	Elmusrati A, Wang J and Wang CY: Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. Int J Oral Sci. 13:242021. View Article : Google Scholar
21	Heusinkveld M, Goedemans R, Briet RJP, Gelderblom H, Nortier JWR, Gorter A, Smit VTHBM, Langeveld APM, Jansen JC and van der Burg SH: Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int J Cancer. 131:E74–E85. 2012. View Article : Google Scholar
22	Hoffmann TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann U, Myers EN, Appella E, DeLeo AB and Whiteside TL: Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264–272) peptide in the circulation of patients with head and neck cancer. Cancer Res. 62:3521–3529. 2002.
23	Hoffmann TK, Nakano K, Elder EM, Dworacki G, Finkelstein SD, Appella E, Whiteside TL and DeLeo AB: Generation of T cells specific for the wild-type sequence p53(264–272) peptide in cancer patients: Implications for immunoselection of epitope loss variants. J Immunol. 165:5938–5944. 2000. View Article : Google Scholar
24	Ikeguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukumoto Y, Yamada Y, Fukuda K, Saito H and Tatebe S: Serum interleukin-6 and −10 levels in patients with gastric cancer. Gastric Cancer. 12:95–100. 2009. View Article : Google Scholar
25	Wang H, Wang L, Chi PD, Wang WD, Chen XQ, Geng QR, Xia ZJ and Lu Y: High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma. Br J Cancer. 114:463–468. 2016. View Article : Google Scholar
26	De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E and Catalano G: Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest. 117:365–373. 2000. View Article : Google Scholar
27	Cortes JE, Talpaz M, Cabanillas F, Seymour JF and Kurzrock R: Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: Lack of correlation with prognosis. Blood. 85:2516–2520. 1995. View Article : Google Scholar
28	Evans C, Morrison I, Heriot AG, Bartlett JB, Finlayson C, Dalgleish AG and Kumar D: The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival. Br J Cancer. 94:1412–1419. 2006. View Article : Google Scholar
29	Green VL, Irune E, Prasai A, Alhamarneh O, Greenman J and Stafford ND: Serum IL10, IL12 and circulating CD4+CD25high T regulatory cells in relation to long-term clinical outcome in head and neck squamous cell carcinoma patients. Int J Oncol. 40:833–839. 2012.
30	Kim Y, Yang H, Lee WS, Cheon J, Sang YB, Kang B, Chon HJ and Kim C: High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma. J Cancer. 14:935–942. 2023. View Article : Google Scholar
31	Giunta EF, Barra G, De Falco V, Argenziano G, Napolitano S, Vitale P, Zanaletti N, Terminiello M, Martinelli E, Morgillo F, et al: Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. Sci Rep. 10:176262020. View Article : Google Scholar
32	Rutz S and Ouyang W: Regulation of interleukin-10 expression. Adv Exp Med Biol. 941:89–116. 2016. View Article : Google Scholar
33	Huo JL, Wang YT, Fu WJ, Lu N and Liu ZS: The promising immune checkpoint LAG-3 in cancer immunotherapy: From basic research to clinical application. Front Immunol. 13:9560902022. View Article : Google Scholar
34	Joller N and Kuchroo VK: Tim-3, Lag-3, and TIGIT. Curr Top Microbiol Immunol. 410:127–156. 2017.
35	Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, Guo B, Herbert DR, Bulfone A, Trentini F, et al: Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med. 19:739–746. 2013. View Article : Google Scholar
36	Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, et al: Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA. 107:7875–7880. 2010. View Article : Google Scholar